ERBB2 and breast carcinoma: Using another therapeutic approach, FIGHT 101 (NCT02393248) is currently evaluating the addition of pemigatinib to a number of well-characterized cytotoxic chemotherapeutics (gemcitabine, cisplatin, docetaxel), HER2-targeted therapy (trastuzumab) and immunotherapy (pembrolizumab) across solid tumours, including breast cancer.